Groundbreaking: First-Ever HCC RAF Score Accessible Through REST API
First-Ever HCC RAF Score Accessible Through REST API
Check Now
Image depicting the concept of elevating provider support and enhancing concurrent coding for risk adjustment in healthcare.
Elevate Provider Support:
Enhance Your Concurrent Coding
for Risk Adjustment
Check Now
ICD10 PCS Codes X XW XW0 XW04

ICD-10-CM Diagnosis Code

Central Vein(XW04)

  • XW04 Central Vein
    • XW043 Percutaneous
      • XW0430 Spesolimab Monoclonal Antibody
        • XW04306 New Technology Group 6
        • XW04308 New Technology Group 8
      • XW0432 Nerinitide
        • XW04326 New Technology Group 6
      • XW0433 Bentracimab, Ticagrelor Reversal Agent
        • XW0433A New Technology Group 10
      • XW0434 Cefepime-taniborbactam Anti-infective
      • XW0435 Ceftobiprole Medocaril Anti-infective
        • XW04357 New Technology Group 7
        • XW04358 New Technology Group 8
        • XW0435A New Technology Group 10
      • XW0436 Afamitresgene Autoleucel Immunotherapy
        • XW04366 New Technology Group 6
        • XW04367 New Technology Group 7
        • XW04368 New Technology Group 8
      • XW0437 Tabelecleucel Immunotherapy
        • XW04372 New Technology Group 2
        • XW04377 New Technology Group 7
        • XW04378 New Technology Group 8
      • XW0438 Obecabtagene Autoleucel
        • XW04387 New Technology Group 7
        • XW04388 New Technology Group 8
        • XW0438A New Technology Group 10
      • XW0439 Odronextamab Antineoplastic
        • XW04396 New Technology Group 6
        • XW04398 New Technology Group 8
        • XW0439A New Technology Group 10
      • XW043A Ciltacabtagene Autoleucel
        • XW043A6 New Technology Group 6
        • XW043A7 New Technology Group 7
      • XW043B Orca-T Allogeneic T-cell Immunotherapy
        • XW043B3 New Technology Group 3
        • XW043B6 New Technology Group 6
        • XW043B7 New Technology Group 7
        • XW043BA New Technology Group 10
      • XW043C Zanidatamab Antineoplastic
        • XW043C6 New Technology Group 6
        • XW043C7 New Technology Group 7
        • XW043CA New Technology Group 10
      • XW043D Atezolizumab Antineoplastic
        • XW043D6 New Technology Group 6
      • XW043E Etesevimab Monoclonal Antibody
        • XW043E5 New Technology Group 5
        • XW043E6 New Technology Group 6
      • XW043F Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy
        • XW043F3 New Technology Group 3
        • XW043F5 New Technology Group 5
        • XW043F6 New Technology Group 6
        • XW043FA New Technology Group 10
      • XW043G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
        • XW043G5 New Technology Group 5
        • XW043G6 New Technology Group 6
        • XW043G7 New Technology Group 7
      • XW043H Axicabtagene Ciloleucel Immunotherapy
        • XW043H5 New Technology Group 5
        • XW043H6 New Technology Group 6
        • XW043H7 New Technology Group 7
      • XW043J Tisagenlecleucel Immunotherapy
      • XW043K Sulbactam-Durlobactam
        • XW043K9 New Technology Group 9
      • XW043L Lifileucel Immunotherapy
        • XW043L6 New Technology Group 6
        • XW043L7 New Technology Group 7
      • XW043M Brexucabtagene Autoleucel Immunotherapy
      • XW043N Lisocabtagene Maraleucel Immunotherapy
      • XW043P Glofitamab Antineoplastic
        • XW043P9 New Technology Group 9
      • XW043Q Posoleucel
        • XW043Q5 New Technology Group 5
        • XW043Q9 New Technology Group 9
      • XW043R Rezafungin
      • XW043S Iobenguane I-131 Antineoplastic
        • XW043S5 New Technology Group 5
      • XW043W Caplacizumab
    • XW04 Central Vein